North Central Neurology Associates, PC

Cullman, Alabama 35058

0 studies enrolling now · 16 studies all time

What they study most

Central Neuropathic Pain, Clinically Isolated Syndrome, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Parkinson Disease Psychosis, Relapsing Multiple Sclerosis, Relapsing-Remitting Multiple Sclerosis

Studies at this site

• A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation — Running, not enrolling
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS — Running, not enrolling
• A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) — Completed
• A Study to Evaluate Efficacy, Safety, and Tolerability of EID of Natalizumab (BG00002) in Participants With RRMS Switching From Treatment With Natalizumab SID in Relation to Continued SID Treatment- Followed by Extension Study Comprising SC and IV Natalizumab Administration — Completed
• Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis — Completed
• The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study — Stopped early
• ACTH for Fatigue in Multiple Sclerosis Patients — Completed
• An Extension Protocol for Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two — Completed
• Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis — Stopped early
• Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS — Completed
• Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One — Completed
• Autologous T Cell Vaccine (TCV) for Multiple Sclerosis — Completed
• Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis — Completed
• Long Term Study of Fingolimod in MS Patients From the FTY Clinical Program — Completed
• Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis — Completed